Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 8;13:860268. doi: 10.3389/fgene.2022.860268

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Hou, Xu, Liu, Yang, Li, Zhao and Jiang.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Construction and validation of mRNAsi-related signature for LUAD patients. (A) Lasso regression identified the prognostic model in LUAD. (B) Cross-validation to select the optimal tuning parameter (λ). The red dotted vertical line crosses over the optimal log λ. (C) The relationship among nine key genes. The bigger the circle size, the more correlative two genes are. (D) The heatmap shows the expression of the 9 genes in high-risk and low-risk LUAD patients. The distribution of clinicopathological characteristics was compared between the high-risk and low-risk groups. *p < 0.05, **p < 0.01 and ***p < 0.001. (E) Risk score distribution of patients in the prognostic model. (F) Survival status scatter plots for patients in the prognostic model. (G) Kaplan-Meier curve analysis of the high-risk and low-risk groups. (H) Time-dependent ROC curve analysis of the prognostic model.